TYR and melanoma: In a previous paper (Osella-Abate et al, 2000), we demonstrated that the majority of untreated stage IV melanoma patients were positive, whereas chemotherapy administration was able to reduce tyrosinase rate, suggesting that tyrosinase may provide a measure of therapy response and be a predictor of disease evolution.